Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Vet Parasitol ; 327: 110144, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38354457

ABSTRACT

The larvae of the nasal bot, Oestrus ovis, mainly parasitize sheep and goats and some species of wild Caprinae but other mammals and humans are also vulnerable to infestation. Eprinomectin 5 mg/mL topical solution (EPRINEX® Multi, Boehringer Ingelheim) administered at 1 mg eprinomectin per kg body weight pour on was recently authorized as an anthelmintic for sheep and goats with zero hours milk withdrawal in several countries in Europe. As the product in cattle has claims against a broad range of parasites including insect parasites and activity against O. ovis has previously been reported following extra-label use in sheep, its therapeutic efficacy against ovine and caprine O. ovis myiasis was evaluated in three regulatory compliant, masked clinical studies. Pre-study recovery of O. ovis larvae from five or six of six randomly selected animals per study site (Bulgaria, one site, sheep; Greece, two sites, sheep or goats) supported the inclusion of the animals from those sites into the studies. The study animals (34 animals per study) were ranked based on bodyweight and allocated randomly to remain untreated (control) or to be treated with eprinomectin 5 mg/mL topical solution at 1 mL per 5 kg body weight pour on. Treatment efficacy was determined based on O. ovis larval counts of eprinomectin 5 mg/mL topical solution-treated vs. untreated animals three weeks after treatment administration. Live O. ovis larvae, including all three instars in each study, were recovered from 13 or 16 of the 17 control animals in the sheep studies (range, 1 to 14 or 5 to 18 larvae, respectively) and from all 17 controls in the goat study (range, 7 to 18 larvae). In each study, eprinomectin 5 mg/mL topical solution-treated animals had significantly (p < 0.001) fewer live O. ovis larvae than the controls. Efficacy of the treatment was 100% and 91.3% against the combined parasitic O. ovis larval stages in sheep and in goats, respectively. The treatment was well accepted by all animals and no health problems were observed throughout the studies. The results of these studies demonstrated eprinomectin 5 mg/mL topical solution administered pour on at 1 mL per 5 kg body weight to be an efficacious and safe treatment of ovine and caprine oestrosis.


Subject(s)
Cattle Diseases , Diptera , Goat Diseases , Ivermectin , Myiasis , Sheep Diseases , Animals , Cattle , Body Weight , Goat Diseases/drug therapy , Goat Diseases/parasitology , Goats , Ivermectin/analogs & derivatives , Larva , Myiasis/drug therapy , Myiasis/veterinary , Myiasis/parasitology , Sheep , Sheep Diseases/drug therapy , Sheep Diseases/parasitology
2.
J Med Entomol ; 59(2): 598-606, 2022 03 16.
Article in English | MEDLINE | ID: mdl-34935041

ABSTRACT

The effects of tsetse-transmitted trypanosomosis control in high tsetse flies (Glossina spp.) challenge and trypanocidal drug resistance settings remain poorly understood in Togo owing to poor data coverage on the current disease impact. From March 2014 to November 2017, a database of zoo-sanitary surveys integrating the evolution of disease incidence and intervention coverage made it possible to quantify the apparent effects attributable to the control effort, focused on all sedentary cattle breeds in the 1,000 km² area of Mô in Togo. The strategy involved an initial phase with cross-sectional entomological and parasitological. Then, three times a year, 20% of the bovine animals of the study area received α-cypermethrin pour-on, and infected cattle with poor health (798 cattle in 2014 and 358 in 2017) were individually given diminazene aceturate at 7 mg/kg of body weight. The tsetse density in the area decreased significantly, from 1.78 ± 0.37 in March 2014 before the α-cypermethrin application to 0.48 ± 0.07 in February 2017. The α-cypermethrin pour-on application and diminazene aceturate treatment of cattle led to the largest reduction in disease incidence, from 28.1% in 2014 to 7.8% in 2017, an improvement in hematocrit from 24.27 ± 4.9% to 27.5 ± 4.6%, and a reduction in calf mortality from 15.9 ± 11% to 5.9%. Improved access to these interventions for different types of livestock and maintaining their effectiveness, despite high tsetse (Diptera: Glossinidae) challenges, should be the primary focus of control strategies in many areas of Togo.


Subject(s)
Cattle Diseases , Heteroptera , Trypanosoma , Trypanosomiasis, African , Tsetse Flies , Animals , Cattle , Cattle Diseases/drug therapy , Cattle Diseases/epidemiology , Cross-Sectional Studies , Diminazene/analogs & derivatives , Pyrethrins , Togo , Trypanosomiasis, African/drug therapy , Trypanosomiasis, African/epidemiology , Trypanosomiasis, African/veterinary
3.
Vet Parasitol ; 298: 109525, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34274762

ABSTRACT

The influence of route of administration on the pharmacokinetics and efficacy of macrocyclic lactone anthelmintics has been a subject of interest due to its potential to influence the development of anthelmintic resistance. For most parasite species studied so far, oral administration results in the highest concentrations of drug in the parasites and the highest efficacy against resistant genotypes. However, a recent study in cattle measured the highest levels of ivermectin in the abomasal Ostertagia ostertagi following subcutaneous injection, but it was not possible to correlate these elevated levels with efficacy. Therefore, the current study was initiated to determine whether injectable delivery might be optimal for attaining high efficacy against this important group of parasites. Three on-farm trials were conducted to measure the efficacy of moxidectin administered by the oral, injectable, and pour-on routes against Ostertagiinae parasites in farmed red deer. Groups of rising 1-year old stags (red or red-wapiti crossbreds) in the 84-104 kg weight range were randomised on liveweight into treatment groups of 6 (1 farm) or 8 (2 farms). Animals were treated to individual liveweight with moxidectin oral (0.2 mg/kg), injectable (0.2 mg/kg), pour-on (0.5 mg/kg) or remained untreated. Twelve days later all animals were euthanised and abomasa recovered for worm count. Adult worms were counted in a 2% aliquot of abomasal washings, and adult and fourth stage larvae in a 10 % aliquot following mucosal incubation in physiological saline. In addition, blood was collected from the same 5 animals in each of the treatment groups on days 0, 1, 2, 3, 5, 7 and 12 after treatment and moxidectin levels in plasma were determined using a mass spectrometer. The number of Ostertagiinae surviving treatment was significantly different for each of the treatment groups with injectable administration being most effective, oral administration being the next most effective and pour-on administration the least effective. This applied to both adult worms and fourth stage larvae. A similar pattern was seen in the levels of moxidectin in plasma with both the peak value and area under the concentration curve being highest following injectable administration and lowest following pour-on treatment. Although undertaken in a different host species, the results support the proposition that injectable administration of macrocyclic lactone anthelmintics is likely to be optimal for efficacy against Ostertagiinae parasites and potentially useful in slowing the emergence of resistance in these parasites.


Subject(s)
Anthelmintics , Cattle Diseases , Deer , Macrolides , Ostertagia , Animals , Anthelmintics/pharmacology , Anthelmintics/therapeutic use , Cattle , Cattle Diseases/drug therapy , Deer/parasitology , Farms , Feces , Macrolides/pharmacology , Macrolides/therapeutic use , Ostertagia/drug effects , Parasite Egg Count/veterinary
4.
Animals (Basel) ; 10(2)2020 Jan 22.
Article in English | MEDLINE | ID: mdl-31978947

ABSTRACT

Infectious bovine keratoconjunctivitis (IBK) caused by Moraxella bovis is commonly seen in the summer months spread by face flies. This trial investigated the difference in incidence of IBK cases from natural exposure between two groups of animals, one treated with Cypermethrin pour-on preparation (PON, n = 98) and one with Cypermethrin impregnated ear tags (TAG, n = 99). Daily Live Weight Gain (DLWG) difference was investigated between animals with cases and those without and between treatment groups. A randomised positive control study, enrolled 197 animals split into two treatment groups. Cases of IBK and DLWG were recorded over the grazing season (April-November 2018). Fifty-four cases of IBK were recorded. There was no association between the two treatment groups (p = 0.362) and case status. Breed and under 12 months old were significant factors for having a case; (OR 2.3, p = 0.014 and OR 3.5, p < 0.001 respectively). There was no difference in DLWG between animals that had a case and animals that had not (p = 0.739) or between the two treatment groups (p = 0.215). Based on our results, there is no significant difference between PON or TAG preparations in the prevention of IBK. Younger animals and white-faced breeds are significantly more likely to suffer with IBK.

5.
J Dairy Sci ; 102(7): 6418-6430, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31030917

ABSTRACT

Lameness is a common animal health condition with significant production and welfare implications. The transdermal formulation of flunixin meglumine is the only approved drug for pain control in cattle in the United States. Thirty adult dairy cows were enrolled in a study to determine the effect of transdermal flunixin on cattle with induced lameness. Cows were allocated to 1 of 3 treatment groups, with 10 cows per group: lameness and flunixin (L+F), lameness and placebo (L+P), or sham induction and placebo (S+P). An arthritis-synovitis was induced in the distal interphalangeal joint of the left hind lateral digit, using 20 mg of amphotericin B, 6 h before the application of treatment. Cows enrolled into the sham induction group had 4 mL of isotonic saline injected into the joint. Cows were dosed with transdermal flunixin at 3.33 mg/kg (1 mL/15 kg), or a placebo at 1 mL/15 kg, every 24 h for 3 d. The first treatment of flunixin or placebo was considered the start of the study, identified as time 0 h. Data were collected from all cows for 120 h following the initial treatment application. Outcome measures included plasma cortisol; substance P; visual lameness assessment; mechanical nociception threshold (MNT), presented as difference between left and right feet; infrared thermography (IRT), presented as difference between left and right feet; and gait analysis using a pressure mat. Cortisol concentrations were lower for the L+F group starting at 1.5 h after drug administration. Substance P levels showed no evidence for treatment differences among groups. Differences between the left hind MNT and right hind MNT were detected, with S+P having the lowest difference at -0.04 kilograms-force (kgf; 95% CI: -1.86 to 1.78 kgf), and L+P having the highest at -2.96 kgf (95% CI: 1.55 to 4.36 kgf). The L+F group was intermediate at -2.08 kgf (95% CI: 0.89 to 3.27 kgf). Similarly, when the difference between the maximum temperatures of the coronary band were examined via IRT, the L+P group had the highest difference at 1.64°C (95% CI: 1.02 to 2.26°C), with the L+F and S+P groups measuring 0.57°C (95% CI: 0.06 to 1.08°C) and 0.53°C (95% CI: -0.2 to 1.25°C) respectively. We found no evidence for differences among treatment groups when analyzing force, contact pressure, step impulse, or stride length. Based on differences in MNT, IRT, and cortisol, transdermal flunixin is an effective analgesic agent for induced lameness. Multiple doses of transdermal flunixin may be required to be clinically effective, based on MNT and IRT data. Further investigation of transdermal flunixin and its analgesic effects is warranted in naturally occurring lameness.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Clonixin/analogs & derivatives , Lameness, Animal/drug therapy , Administration, Cutaneous , Analgesics/administration & dosage , Animals , Cattle , Clonixin/administration & dosage , Female , Gait/drug effects , Hydrocortisone/blood , International Cooperation , Lameness, Animal/physiopathology , Male , Pain Management/veterinary
6.
Bull Entomol Res ; 109(2): 191-198, 2019 Apr.
Article in English | MEDLINE | ID: mdl-29784064

ABSTRACT

Effects of the antiparasitic drug eprinomectin were studied on the dung beetles, Onthophagus lenzii Harold and the rare species, Copris ochus Motschulsky by pour-on administrations (500 µg kg-1) in Japan. Eprinomectin was detected in cattle dung from 1 to 7 or 14 days after treatment, with a peak at 1 day after treatment in two experiments. In O. lenzii, adult survivals and numbers of brood balls constructed were significantly reduced in dung from eprinomectin-treated cattle at 1 and 3 days post-treatment in experiment 1, and adult emergence rates were extremely reduced in dung at 1, 3, and 7 days post-treatment. In C. ochus, adult survivals were significantly reduced in dung at 3 days post-treatment (experiment 1), and equivalent levels to the control were restored in dung at 7 and 14 days post-treatment (experiment 2). Numbers of brood balls of C. ochus were nil in dung at 3 days (experiment 1), and significantly reduced in dung at 7 days (experiment 2) post-treatment compared with control. Adult emergence rates of C. ochus were 100 and 71.6% in dung from control cattle in experiments 1 and 2, respectively. However, no oviposition was observed in dung at 3 days post-treatment, and all offspring died at egg or the first instar larval stage in dung from 7 and 14 days post-treatment. Feeding activities of O. lenzii and C. ochus were significantly inhibited in dung from treated cattle at 1-3 days and 3 days post-treatment, respectively, returning to levels of the control at 7 days post-treatment.


Subject(s)
Anthelmintics/toxicity , Coleoptera , Ivermectin/analogs & derivatives , Animals , Feeding Behavior/drug effects , Female , Ivermectin/toxicity , Male , Reproduction/drug effects , Toxicity Tests
7.
J Vet Pharmacol Ther ; 42(1): 111-115, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30393987

ABSTRACT

The pharmacokinetic parameters of moxidectin (MXD) after intravenous and pour-on (topical) administration were studied in sixteen pigs at a single dose of 1.25 and 2.5 mg/kg BW (body weight), respectively. Blood samples were collected at pretreatment time (0 hr) over 40 days. The plasma kinetics were analyzed by WinNonlin 6.3 software through a noncompartmental model. For intravenous administration (n = 8), the elimination half-life (λZ ), the apparent volume of distribution (Vz ), and clearance (Cl) were 10.29 ± 1.90 days, 89.575 ± 29.856 L/kg, and 5.699 ± 2.374 L/kg, respectively. For pour-on administration (n = 8), the maximum plasma drug concentration (Cmax ), time to maximum plasma concentration (Tmax ), and λZ were 7.49 ng/ml, 1.72, and 6.20 days, respectively. MXD had a considerably low absolute pour-on bioavailability of 9.2%, but the mean residence time (MRT) for pour-on administration 10.88 ± 1.75 days was longer than 8.99 ± 2.48 days for intravenous administration. These results showed that MXD was absorbed via skin rapidly and eliminated slowly. The obtained data might contribute to refine the dosage regime for topical MXD administration.


Subject(s)
Antiparasitic Agents/pharmacokinetics , Macrolides/pharmacokinetics , Swine/metabolism , Administration, Cutaneous , Animals , Antiparasitic Agents/administration & dosage , Antiparasitic Agents/blood , Half-Life , Injections, Intravenous/veterinary , Macrolides/administration & dosage , Macrolides/blood , Male , Swine/blood
8.
J Vet Pharmacol Ther ; 41(3): 490-493, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29460288

ABSTRACT

A transdermal formulation of the nonsteroidal anti-inflammatory drug, flunixin meglumine, has been approved in the United States and Canada for single-dose administration. Transdermal flunixin meglumine was administered to 10 adult Holstein cows in their second or third lactation at the label dose of 3.33 mg/kg every 24 hr for three total treatments. Plasma flunixin concentrations were determined using high-pressure liquid chromatography with mass spectroscopy (HPLC-MS). Pharmacokinetic analysis was completed on each individual animal with noncompartmental methods using computer software. The time to maximum drug concentration (Tmax) was 2.81 hr, and the maximum drug concentration was 1.08 µg/ml. The mean terminal half-life (T½) was determined to be 5.20 hr. Clearance per fraction absorbed (Cl/F) was calculated to be 0.294 L/hr kg-1 , and volume of distribution of fraction (Vz/F) absorbed was 2.20 L/kg. The mean accumulation factor was 1.10 after three doses. This indicates changes in dosing may not be required when giving multiple doses of flunixin transdermal. Further work is required to investigate the clinical efficacy of transdermal flunixin after multiple daily doses.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Clonixin/analogs & derivatives , Administration, Cutaneous , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/blood , Area Under Curve , Cattle , Clonixin/administration & dosage , Clonixin/blood , Clonixin/pharmacokinetics , Drug Administration Schedule , Drug Residues , Female , Half-Life
9.
Res Vet Sci ; 114: 294-296, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28605693

ABSTRACT

The effect of flunixin transdermal pour-on solution (Finadyne® Transdermal; MSD Animal Health) on prostaglandin E2 (PGE2) synthesis in bovine inflammatory exudate was evaluated in a tissue cage model of acute inflammation. Twelve calves were randomly allocated to two-treatment groups over two sequences. Three weeks prior to the first period, sterile hollow perforated polyethylene balls were surgically embedded in the subcutis at four distinct sites in each animal. On the first day of each period, an aseptic inflammation was induced by injecting 0.5mL of a 2% carrageenan solution into the lumen of each tissue cage. Treatment with either flunixin transdermal or negative control (NaCl) immediately followed. 0.5mL of exudate was collected prior to challenge, and at 2, 4, 8, 12, 24, 36 and 48h after challenge. Exudate PGE2 concentrations were analyzed using ultra-high pressure liquid chromatography coupled with tandem mass spectrometry method. Mean PGE2 concentrations were consistently lower in calves treated with flunixin transdermal than those measured in calves treated with negative control, indicating an inhibitory activity on cyclooxygenase. Inhibition was the highest at 8h after treatment, and differences with the negative control were significant at +8, 24, 36 and 48h. The flunixin transdermal formulation was effective in reducing PGE2 concentrations in bovine exudate following an induced inflammation. Its anti-inflammatory action started in the first hours after treatment and lasted up to 48h.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cattle Diseases/drug therapy , Clonixin/analogs & derivatives , Dinoprostone/biosynthesis , Inflammation/veterinary , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cattle , Cattle Diseases/immunology , Clonixin/administration & dosage , Clonixin/therapeutic use , Exudates and Transudates/immunology , Inflammation/drug therapy , Inflammation/immunology , Random Allocation
10.
Parasitol Res ; 116(3): 929-938, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28058537

ABSTRACT

The control of Rhipicephalus microplus is essential to prevent cattle discomfort and economic losses. However, increased resistance and acaricides inefficiency lead producers to adopt strategies that could result in the accumulation of chemical residues in meat and milk with possibilities of poisoning in animals and people. This scenario demonstrates the necessity of research into the identification of novel, effective and environmentally safe therapeutic options for cattle tick control. The objectives of this study were to develop and assess the efficacy of R. microplus biotherapic and of 5% eugenol for the control of R. microplus in artificially infested calves. Eighteen male 6-month-old Holstein calves were divided into three groups of six animals. In Group 1, the animals did not receive medication (control group); in Group 2, the animals received 1 mL of R. microplus biotherapic at dilution 6CH (centesimal Hahnemannian), orally administered twice daily. And in Group 3, they received a single application of eugenol 5% in the pour-on formulation. The median efficacy for biotherapy and eugenol 5% was respectively 10.13 and 13.97%; however, upon analyzing reproductive efficiency, it is noteworthy that the biotherapic had 45.86% efficiency and was superior to the action of eugenol (12.03%) after 37 days of treatment. The ultrastructural study provided information about the effects of R. microplus biotherapic on the ovaries of engorged females and showed disorganization in the deposition of the oocyte exochorion. The results suggest hatchability inhibition of larvae, interference in R. microplus reproduction and future possibilities for eco-friendly control of R. microplus with biotherapic 6CH.


Subject(s)
Acaricides/administration & dosage , Cattle Diseases/drug therapy , Eugenol/administration & dosage , Rhipicephalus/drug effects , Tick Infestations/veterinary , Acaricides/chemistry , Animals , Cattle , Cattle Diseases/parasitology , Drug Compounding , Eugenol/chemistry , Female , Larva/drug effects , Larva/physiology , Male , Reproduction/drug effects , Rhipicephalus/physiology , Tick Control , Tick Infestations/drug therapy , Tick Infestations/parasitology , Treatment Outcome
11.
J Arthropod Borne Dis ; 10(1): 78-86, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27047974

ABSTRACT

BACKGROUND: Visceral leishmaniasis (VL) is one of the most important parasitic zoonotic diseases in the world. Domestic dogs are the main domestic reservoirs of VL in endemic foci of Iran. Various methods, including vaccination, treatment of dogs, detection and removal of infected dogs have different results around the world. General policy on control of canine visceral leishmaniasis is protection of them from sand fly bites. The aim of this study was evaluation of pour-on application of flumethrin on dogs against blood-feeding and mortality of field-caught sand flies. METHODS: Once every 20 days from May untill September 2013, the treated and control dogs were exposed with field caught sandflies for 2 hours under bed net traps. After the exposure time, both alive and dead sand flies were transferred in netted cups to the laboratory. The mortality rate of them was assessed after 24 hours. The blood-fed or unfed conditions were determined 2 hours after exposure to the dogs under stereomicroscope. RESULTS: The blood feeding index was varied from 12.0 to 25.0 % and 53.0 to 58.0 % for treated and control dogs respectively (P< 0.0001). The blood feeding inhibition was 75.0-87.0 % and 41.0-46.0 % for the control and treated dogs (P< 0.0001), respectively.The total mortality rate was 94.0-100 % and 19.0-58.0 % respectively for the treated and control groups (P< 0.001). CONCLUSTION: Application of pour-on flumethrin on dogs caused 90-100 % mortality until 2.5 month and inhibited the blood-feeding of sand flies.

12.
N Z Vet J ; 64(4): 207-11, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26820168

ABSTRACT

AIMS: To investigate the plasma disposition and faecal excretion of eprinomectin (EPM) in non-lactating dairy cattle following topical and S/C administration. METHODS: Holstein dairy cows, 3.5-5 years-old, were selected 20-25 days after being dried off and were randomly allocated to receive EPM either topically (n=5) or S/C (n=5) at dose rates of 0.5 and 0.2 mg/kg bodyweight, respectively. Heparinised blood and faecal samples were collected at various times between 1 hour and 30 days after treatment, and were analysed for concentrations of EPM using high performance liquid chromatography with a fluorescence detector. RESULTS: The maximum concentration of EPM in plasma (Cmax) and the time to reach Cmax were both greater after S/C administration (59.70 (SD 12.90) ng/mL and 1.30 (SD 0.27) days, respectively) than after topical administration (20.73 (SD 4.04) ng/mL and 4.40 (SD 0.89) days, respectively) (p<0.001). In addition, S/C administration resulted in greater plasma availability (area under the curve; AUC), and a shorter terminal half-life and mean residence time (295.9 (SD 61.47) ng.day/mL; 2.95 (SD 0.74) days and 4.69 (SD 1.01) days, respectively) compared with topical administration (168.2 (SD15.67) ng.day/mL; 4.63 (SD 0.32) days, and 8.23 (SD 0.57) days, respectively) (p<0.01). EPM was detected in faeces between 0.80 (SD 0.45) and 13.6 (SD 4.16) days following S/C administration, and between 1 (SD 0.5) and 20.0 (SD 3.54) days following topical administration. Subcutaneous administration resulted in greater faecal excretion than topical administration, expressed as AUC adjusted for dose (1188.9 (SD 491.64) vs. 311.5 (SD 46.90) ng.day/g; p<0.05). Maximum concentration in faeces was also higher following S/C than topical administration (223.0 (SD 63.96) vs. 99.47 (SD 43.24) ng/g; p<0.01). CONCLUSIONS: Subcutaneous administration of EPM generated higher plasma concentrations and greater plasma availability compared with topical administration in non-lactating cattle. Although the S/C route provides higher faecal concentrations, the longer faecal persistence of EPM following topical administration may result in more persistent efficacy preventing establishment of incoming nematode larvae in cattle.


Subject(s)
Anthelmintics/pharmacokinetics , Feces/chemistry , Ivermectin/analogs & derivatives , Administration, Topical , Animals , Anthelmintics/administration & dosage , Anthelmintics/blood , Anthelmintics/chemistry , Area Under Curve , Cattle , Female , Half-Life , Ivermectin/administration & dosage , Ivermectin/blood , Ivermectin/chemistry , Ivermectin/pharmacokinetics , Subcutaneous Absorption
13.
Int J Parasitol Drugs Drug Resist ; 5(3): 172-7, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26448903

ABSTRACT

Control of Fasciola hepatica infection in livestock is based on annual treatment using flukicides such as triclabendazole, albendazole and closantel. However, triclabendazole resistant F. hepatica populations are emerging worldwide and resistance is emerging to albendazole, whereas it has until now never been described for closantel. In Sweden, a topical formulation containing a combination of closantel and ivermectin (Closamectin Pour On) has been registered for use in cattle only since 2011. This study evaluated the efficacy of closantel against F. hepatica in naturally infected beef cattle using both coproantigen and faecal egg count reduction tests. Faecal egg counts (FEC) and coproantigen ELISA examinations were conducted in February 2014 in three beef cattle herds (A, B, C) in south-western Sweden. On each farm, 10 F. hepatica coproantigen-positive and F. hepatica egg-positive animals were allocated after 12-16 weeks of housing into groups and treated topically with a minimum of 20 mg closantel per kg body weight. Faecal samples were collected from selected animals on 0, 7 and 21 day post-treatment (PT). Based on FEC, closantel efficacy 21 days PT was 72% (95% CI: 65-77%) and 97% (95% CI: 95-98%) on farms A and B, respectively. No FEC reduction at all was observed on farm C. In total, 4, 1 and 6 animals remained coproantigen-positive at 21 days PT on farms A, B and C, respectively. Closantel treatment failure was confirmed on two of the farms. As the animals were housed 12-16 weeks before treatment and thereafter during the entire study, failure due to the presence of juvenile flukes was excluded. Although the cause of closantel failure currently remains unclear, development of resistance or/and absorption failure of topical administration should be considered. To our knowledge, this is the first report of closantel treatment failure against F. hepatica in cattle.


Subject(s)
Anthelmintics/therapeutic use , Cattle Diseases/parasitology , Fasciola hepatica/drug effects , Fascioliasis/veterinary , Salicylanilides/therapeutic use , Animals , Anthelmintics/pharmacology , Cattle , Cattle Diseases/drug therapy , Cattle Diseases/epidemiology , Drug Resistance , Fascioliasis/drug therapy , Fascioliasis/epidemiology , Fascioliasis/parasitology , Feces/parasitology , Parasite Egg Count , Salicylanilides/pharmacology , Sweden/epidemiology , Treatment Failure
14.
Pesqui. vet. bras ; 34(11): 1094-1100, nov. 2014. tab
Article in English | LILACS, VETINDEX | ID: lil-736035

ABSTRACT

The objective of the study was to evaluate the efficacy of pour-on formulations of fluazuron and ivermectin in different therapeutic protocols for treatment of demodicosis by means of quantifying mites with skin scraping, histological and clinical evaluation in dogs. Eighteen dogs with skin scrapings positive for Demodex canis were evaluated, divided into three groups. All the animals were treated every 14 days, completing 6 treatments for each animal (days 0, 14, 28, 42, 56 and 70). In group 1, pour-on 2.5% fluazuron was used at the dose of 20mg/kg; in the group 2 pour-on 2.5% fluazuron at a dose of 20 mg/kg in association with pour-on 0.5% ivermectin at the dose of 0.6mg/kg; and in group 3, pour-on 0.5% ivermectin alone was used, at the dose of 0.6mg/kg. The treatment was evaluated and monitored through skin scrapings and clinical follow-up of the lesions every 14 days for 84 days, and through histopathological examination at the end of each treatment protocol. The success rate was defined as the percentage of dogs in each group that had negative skin scrapings after the treatment: this was 16.67% for group 1, and 50% for groups 2 and 3. The reduction in mite counts reached effectiveness of 67.66%, 88.99% and 84.29% for groups 1, 2 and 3 respectively. The Wilcoxon test showed that there was a significant difference between the number of mites before and after treatment in groups 2 and 3. The histopathological examination revealed that only group 1 showed no significant difference in the intensity of infestation between days 0 and 84. Clinically, there was no significant difference between the evaluation before and after treatment in the three groups. pour-on 2.5% fluazuron and pour-on 0.5% ivermectin were not effective for treating canine demodicosis, either in association or as single therapy, when applied every 14 days for a period of 70 days. Quantification of mites using skin scrapings and histological evaluation proved to be ineffective, either one as sole therapeutic evaluation parameters, for canine demodicosis.(AU)


O objetivo do presente estudo foi avaliar a eficácia do fluazuron e da ivermectina pour-on em diferentes protocolos terapêuticos no tratamento da demodiciose, através da quantificação de ácaros por raspados cutâneos e exames histológicos, além da avaliação dos cães. Foram avaliados 18 cães com raspados cutâneos positivos para o ácaro Demodex canis, divididos em três grupos. Todos os animais foram tratados a cada 14 dias, totalizando seis tratamentos em cada cão (Dias 0, 14, 28, 42, 56 e 70). No grupo 1 foi utilizado fluazuron 2,5% pour-on na dosagem de 20mg/kg; no grupo 2 foi empregado fluazuron 2,5% pour-on na dosagem de 20mg/kg associado a ivermectina 0,5% pour-on, na dosagem de 0,6mg/kg e, no grupo 3, somente ivermectina 0,5% pour-on 0,6mg/kg. Raspados cutâneos e acompanhamento clínico das lesões foram realizados a cada 14 dias por 84 dias e realizado exame histopatológico ao final de cada protocolo terapêutico. A taxa de sucesso foi definida pela porcentagem de cães em cada grupo com raspados negativos ao final do tratamento, que foi 16,67% para o grupo 1 e 50% para os grupos 2 e 3. A redução na contagem no número de ácaros alcançou eficácia de até 67,66%; 88,99% e 84,29%, nos grupos 1, 2 e 3, respectivamente. O teste de Wilcoxon mostrou que houve diferença significativa entre a quantidade de ácaros antes e após o tratamento nos grupos 2 e 3. No exame histopatológico apenas o grupo 1 não apresentou diferença significativa na intensidade da infestação entre os dias 0 e 84. Clinicamente não houve diferença significativa entre as avaliações antes e após o tratamento dos três grupos. O fluazuron 2,5% pour-on e a ivermectina 0,5% pour-on associados ou como terapia única, não foram eficazes no tratamento da demodiciose canina, quando aplicados a cada 14 dias em um período de 70 dias. A quantificação de ácaros através do exame parasitológico em raspado cutâneo e em exame histopatológico demonstrou-se ineficaz como parâmetro isolado de avaliação pós-terapêutica para demodiciose canina.(AU)


Subject(s)
Animals , Dogs , Ivermectin/administration & dosage , Mites/drug effects , Skin Diseases, Parasitic/veterinary , Administration, Cutaneous
15.
Med Vet Entomol ; 28(2): 210-6, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24191962

ABSTRACT

Among peridomestic structures, chicken coops are sites of major importance for the domestic ecology of Triatoma infestans (Hemiptera: Reduviidae). The aim of this study was to evaluate in an experimental context the effects of a cypermethrin pour-on formulation applied to chickens on blood intake, moulting and mortality in T. infestans, under the natural climatic conditions of a region endemic for Chagas' disease. Experimental chicken huts were made of bricks and covered with plastic mosquito nets. Ninety fourth-instar nymphs were maintained in each hut. The study used a completely random design in which chickens in the experimental group were treated with a cypermethrin pour-on formulation. Five replicates (= huts) of the experimental and control groups were conducted. The number of live T. infestans, blood intake and moults to fifth-instar stage were recorded at 1, 5, 20, 35 and 45 days after the application of cypermethrin. Cumulative mortality was higher in nymphs exposed to treated chickens (> 71%) than in control nymphs (< 50%) (P < 0.01). Blood intake and moulting rate were lower in nymphs fed on treated chickens than in control nymphs (P < 0.05). Pour-on cypermethrin was able to cause significant mortality, although it did not eliminate the experimental population of T. infestans.


Subject(s)
Chagas Disease/prevention & control , Insect Vectors , Insecticides , Pyrethrins , Triatoma , Animals , Argentina , Chickens , Feeding Behavior/drug effects , Insecticides/pharmacology , Longevity/drug effects , Molting/drug effects , Nymph , Pyrethrins/pharmacology , Random Allocation , Time Factors , Triatoma/growth & development
16.
Mem. Inst. Oswaldo Cruz ; 107(8): 1011-1015, Dec. 2012. graf, tab
Article in English | LILACS | ID: lil-660648

ABSTRACT

Triatoma infestans is the main vector of Trypanosoma cruzi, the aetiological agent of Chagas disease in the Gran Chaco region of South America. As a frequent blood meal source for triatomine bugs, domestic goats play a key role in the eco-epidemiology of Chagas disease. The aim of this study was to evaluate the mortality and blood intake of T. infestans fed on goats that had been treated with different doses of pour-on insecticide. Third-instar nymphs were fed on goats that had been treated with 0 cc, 5 cc, 10 cc or 15 cc of a pour-on formulation of cypermethrin. The exposure of T. infestans to animals treated at different post-application intervals revealed a residual activity of the insecticide. The mortality rate in the treated groups was higher than in the control groups until 30 days post-insecticide application (p = 0.03), except in the group treated with 5 cc, in which no mortality was detected after seven days of insecticide application. Rainfall affected the triatomicide effect, reducing the time of residual activity. The cypermethrin pour-on treatment decreased the blood intake of T. infestans. Thirty days after the cypermethrin application, nymph mortality was 16% (± 13) with both doses (10 cc and 15 cc). The 15 cc dose did not result in higher insect mortality or increased persistence compared to the 10 cc dose.


Subject(s)
Animals , Female , Insect Vectors , Insecticides , Pesticide Residues , Pyrethrins , Triatoma , Chagas Disease , Goats , Insect Control
17.
Mem. Inst. Oswaldo Cruz ; 104(3): 481-485, May 2009. graf, tab
Article in English | LILACS | ID: lil-517014

ABSTRACT

This article reports the effects of a pour-on formulation of cypermethrin (6 percent active ingredient) applied to chickens exposed to Triatoma infestans, the main vector of Chagas disease in rural houses of the Gran Chaco Region of South America. This study was designed as a completely random experiment with three experimental groups and five replicates. Third instar nymphs were fed on chickens treated with 0, 1 and 2 cc of the formulation. Nymphs were allowed to feed on the chickens at different time intervals after the insecticide application. Third-instar nymphs fed on treated chickens showed a higher mortality, took less blood during feeding and had a lower moulting rate. The mortality rate was highest seven days after the insecticide solution application and blood intake was affected until 30 days after the application of the solution.


Subject(s)
Animals , Chickens/parasitology , Insect Vectors/drug effects , Insecticides/pharmacology , Pyrethrins/pharmacology , Triatoma/drug effects , Laboratories , Molting/drug effects , Nymph/drug effects , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL